AU2022274309A1 - Psd-95 inhibitors and uses thereof - Google Patents

Psd-95 inhibitors and uses thereof Download PDF

Info

Publication number
AU2022274309A1
AU2022274309A1 AU2022274309A AU2022274309A AU2022274309A1 AU 2022274309 A1 AU2022274309 A1 AU 2022274309A1 AU 2022274309 A AU2022274309 A AU 2022274309A AU 2022274309 A AU2022274309 A AU 2022274309A AU 2022274309 A1 AU2022274309 A1 AU 2022274309A1
Authority
AU
Australia
Prior art keywords
seq
compound according
cpp
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022274309A
Other languages
English (en)
Other versions
AU2022274309A9 (en
Inventor
Christian Reinhard Otto BECH-BARTLING
Vita SEREIKAITE
Kristian STRØMGAARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of AU2022274309A1 publication Critical patent/AU2022274309A1/en
Publication of AU2022274309A9 publication Critical patent/AU2022274309A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022274309A 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof Abandoned AU2022274309A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
EP21173587.3 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2022274309A1 true AU2022274309A1 (en) 2023-09-28
AU2022274309A9 AU2022274309A9 (en) 2024-01-25

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022274309A Abandoned AU2022274309A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Country Status (16)

Country Link
US (1) US20240245793A1 (https=)
EP (1) EP4337673B1 (https=)
JP (1) JP2024520234A (https=)
KR (1) KR20240007140A (https=)
CN (1) CN117295755A (https=)
AU (1) AU2022274309A1 (https=)
BR (1) BR112023021410A2 (https=)
CA (1) CA3218073A1 (https=)
ES (1) ES3040762T3 (https=)
IL (1) IL307244A (https=)
MX (1) MX2023013313A (https=)
PL (1) PL4337673T3 (https=)
SA (1) SA523451347B1 (https=)
TW (1) TW202306965A (https=)
WO (1) WO2022238530A1 (https=)
ZA (1) ZA202308712B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
JP7723457B2 (ja) * 2023-07-03 2025-08-14 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
ES2544573T3 (es) 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
ZA202308712B (en) 2025-02-26
PL4337673T3 (pl) 2026-01-05
KR20240007140A (ko) 2024-01-16
AU2022274309A9 (en) 2024-01-25
US20240245793A1 (en) 2024-07-25
ES3040762T3 (en) 2025-11-04
CN117295755A (zh) 2023-12-26
EP4337673A1 (en) 2024-03-20
JP2024520234A (ja) 2024-05-23
CA3218073A1 (en) 2022-11-17
MX2023013313A (es) 2023-12-04
SA523451347B1 (ar) 2024-08-27
BR112023021410A2 (pt) 2023-12-19
EP4337673B1 (en) 2025-07-09
TW202306965A (zh) 2023-02-16
WO2022238530A1 (en) 2022-11-17
EP4337673C0 (en) 2025-07-09
IL307244A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
EP4337673B1 (en) Psd-95 inhibitors and uses thereof
CA2931694C (en) Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
KR102046830B1 (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
AU2021399076B2 (en) Polypeptides and uses thereof
KR20000069408A (ko) 수용체에 결합하는 펩티드 및 화합물
KR20020010928A (ko) 인테그린 αｖβ６의 억제제로서의 사이클릭 펩타이드유도체
EP4482578A1 (en) Crf2 receptor agonists and their use in therapy
EP1756160B1 (en) Oligomeric peptides and their use for the treatment of hiv infections
KR20110031280A (ko) 펩티드, 펩티드모방체 및 그 유도체, 그 제조 방법 및 치료적 및/또는 예방적 활성 약학적 조성물의 제조를 위한 그들의 용도
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
CA2937032C (en) Activated neurotensin molecules and the uses thereof
HK40108323A (en) Psd-95 inhibitors and uses thereof
HK40108323B (en) Psd-95 inhibitors and uses thereof
CN116157140A (zh) 具有肾酶促效剂活性的稳定胜肽
JP2024536413A (ja) 二環式ペプチドリガンド薬物コンジュゲート
HK1229227B (en) Fatty acid derivatives of dimeric inhibitors of psd-95

Legal Events

Date Code Title Description
SREP Specification republished